Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - tacrolimus -

ABD - İngilizce - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.3 mg in 1 g - tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). tacrolimus ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

ABD - İngilizce - NLM (National Library of Medicine)

sandoz inc - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.5 mg - tacrolimus capsules are indicated for the prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant [see clinical studies (14.1)] , liver transplant [see clinical studies (14.2)], and heart transplant [see clinical studies (14.3)] , and pediatric patients receiving allogeneic liver transplants [see clinical studies (14.2)] in combination with other immunosuppressants. additional pediatric use information is approved for astellas pharma us, inc.’s prograf (tacrolimus) products. however, due to astellas pharma us, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. tacrolimus capsules are contraindicated in patients with a hypersensitivity to tacrolimus. hypersensitivity symptoms reported include dyspnea, rash, pruritus, and acute respiratory distress syndrome [see adverse reactions (6)] . pregnancy exposure registry there is a pregnancy registry that monitors pregnancy outcomes in women exposed to tacrolimus during pregnancy. the transpl

Kanada - İngilizce - Health Canada

jamp pharma corporation - tacrolimus (tacrolimus monohydrate) - capsule (immediate release) - 1mg - tacrolimus (tacrolimus monohydrate) 1mg - immunosuppressive agents

Kanada - İngilizce - Health Canada

jamp pharma corporation - tacrolimus (tacrolimus monohydrate) - capsule (immediate release) - 5mg - tacrolimus (tacrolimus monohydrate) 5mg - immunosuppressive agents

Kanada - İngilizce - Health Canada

accord healthcare inc - tacrolimus (tacrolimus monohydrate) - capsule (immediate release) - 1mg - tacrolimus (tacrolimus monohydrate) 1mg - immunosuppressive agents

Kanada - İngilizce - Health Canada

accord healthcare inc - tacrolimus (tacrolimus monohydrate) - capsule (immediate release) - 5mg - tacrolimus (tacrolimus monohydrate) 5mg - immunosuppressive agents

ABD - İngilizce - NLM (National Library of Medicine)

accord healthcare inc. - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy  for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). tacrolimus ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

ABD - İngilizce - NLM (National Library of Medicine)

biocon pharma inc. - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus capsules are indicated for the prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant [see clinical studies (14.1) ], liver transplants [see clinical studies (14.2) ] and heart transplant [see clinical studies (14.3) ], and pediatric patients receiving allogeneic liver transplants [see clinical studies (14.2) ] in combination with other immunosuppressants. additional pediatric use information is approved for astellas pharma us, inc.’s prograf (tacrolimus) products. however, due to astellas pharma us, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. tacrolimus capsules are contraindicated in patients with a hypersensitivity to tacrolimus. tacrolimus injection is contraindicated in patients with a hypersensitivity to hco-60 (polyoxyl 60 hydrogenated castor oil). hypersensitivity symptoms reported include dyspnea, rash, pruritus, and acute respiratory distress syndrome [see adverse reactions (6) ]. risk summary tacrolimus ca

ABD - İngilizce - NLM (National Library of Medicine)

kremers urban pharmaceuticals inc. - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.5 mg - tacrolimus capsules usp are indicated for the prophylaxis of organ rejection in patients receiving allogeneic kidney transplants. it is recommended that tacrolimus be used concomitantly with azathioprine or mycophenolate mofetil (mmf) and adrenal corticosteroids [see clinical studies (14.1)] . therapeutic drug monitoring is recommended for all patients receiving tacrolimus capsules usp [see dosage and administration (2.6)] . tacrolimus capsules usp are indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver transplants. it is recommended that tacrolimus be used concomitantly with adrenal corticosteroids [see clinical studies (14.2)] . therapeutic drug monitoring is recommended for all patients receiving tacrolimus capsules usp [see dosage and administration (2.6)] . tacrolimus capsules usp are indicated for the prophylaxis of organ rejection in patients receiving allogeneic heart transplants. it is recommended that tacrolimus capsules usp be used concomitantly with azathioprine